Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Bacillus Calmette Guerin Tice Dru Ita Co Bcg Drug

Bacillus Calmette-Guérin (BCG) Vaccine (TICE DRU Ita Co BCG)

Introduction

The Bacillus Calmette-Guérin (BCG) vaccine is one of the most well-known vaccines in the world, primarily used to protect against tuberculosis (TB), a highly infectious bacterial disease caused by Mycobacterium tuberculosis. The BCG vaccine is named after its creators, Albert Calmette and Camille Guérin, who developed it in the early 20th century. It is derived from a strain of Mycobacterium bovis, a bacterium closely related to M. tuberculosis. The vaccine is often administered in regions where TB is common and plays a crucial role in preventing the spread of this life-threatening disease. In addition to its primary use in TB prevention, BCG has other clinical applications, including bladder cancer treatment and possibly offering protection against certain other infections.

Bacillus Calmette-Guerin

BCG is a live attenuated vaccine made from a weakened strain of Mycobacterium bovis, a bacterium closely related to Mycobacterium tuberculosis. M. bovis causes tuberculosis in cattle and can also infect humans, especially in regions where people live in close contact with cattle. The process of attenuation (weakening) of the bacteria ensures that the BCG vaccine does not cause disease in healthy individuals while still stimulating the body’s immune system to mount a defense against TB.

TICE DRU Ita Co BCG

One of the most common commercial preparations of BCG is TICE DRU Ita Co BCG. This specific version of the BCG vaccine is produced by Tice, a manufacturer that specializes in biologic products. TICE DRU Ita Co BCG is formulated for the treatment of bladder cancer in addition to its use in TB prevention. The TICE formulation is the most widely used in the United States, while other preparations are available in different countries. The DRU Ita Co variant is often used in specialized oncology practices, particularly for immunotherapy for bladder cancer.

Mechanism of Action of BCG

BCG works by stimulating the immune system to recognize and fight against Mycobacterium tuberculosis, the bacterium responsible for tuberculosis. Once administered, BCG is recognized as a pathogen by the body’s immune cells, specifically the macrophages and dendritic cells. These cells process the vaccine and trigger a complex immune response. The adaptive immune system, which is responsible for long-term immunity, is activated and produces both cell-mediated immunity (involving T-cells) and humoral immunity (involving antibodies).

Immune Response Activation

  • Macrophages and Dendritic Cells: These immune cells capture and process the BCG bacteria, which are then presented on their surface. This activates T-cells, particularly helper T-cells (CD4+) and cytotoxic T-cells (CD8+).

  • T-cells Activation: The T-cells respond by recognizing the BCG bacteria and proliferating to produce memory T-cells. These memory cells stay in the body, enabling a quick immune response if the body is exposed to M. tuberculosis in the future.

  • Cytokine Release: The BCG vaccine also stimulates the release of cytokines, which are signaling molecules that help regulate and amplify the immune response. This response not only targets tuberculosis but can also enhance immune defenses against certain cancers.

Clinical Uses of BCG

While the primary clinical use of BCG is in the prevention of tuberculosis, it has other applications, including the treatment of bladder cancer and potential roles in immunotherapy for other cancers. Below, we explore these applications in detail.

1. Tuberculosis Prevention

BCG is most commonly used in countries with a high incidence of tuberculosis. The vaccine is typically given to infants and young children in areas where TB is endemic. The efficacy of BCG in preventing TB varies, but it is generally effective in preventing severe forms of tuberculosis in children, such as miliary TB and meningitis. However, its effectiveness in preventing pulmonary TB in adults is less certain.

  • Global Implementation: BCG is one of the most widely used vaccines in the world, and global TB vaccination programs have been in place for many decades.

  • Long-Term Protection: Although BCG does not guarantee complete immunity against TB, it significantly reduces the risk of developing severe forms of the disease.

2. Bladder Cancer Treatment (Immunotherapy)

BCG is also used as an intravesical therapy for patients with non-muscle-invasive bladder cancer (NMIBC). In this setting, the vaccine is administered directly into the bladder to stimulate an immune response against cancer cells. This treatment is considered one of the most effective immunotherapies for bladder cancer.

  • Mechanism in Cancer: The exact mechanism by which BCG helps treat bladder cancer is not entirely understood, but it is believed that the immune response triggered by the vaccine attacks cancer cells in the bladder. It is thought to involve the activation of T-cells and macrophages that target and kill tumor cells.

  • Indications: BCG is typically used in patients who have high-risk NMIBC or who have had recurrent bladder cancer following initial surgical treatments.

  • Treatment Protocol: BCG is administered directly into the bladder in a series of weekly treatments, with a typical course lasting for 6-12 weeks. Maintenance therapy may be used for patients with high recurrence risk.

3. Other Potential Applications

BCG has been investigated for its potential use in the treatment of other cancers, including melanoma, lung cancer, and leukemia. However, these uses are still in the experimental phase, and more research is needed to confirm its effectiveness in these indications.

Dosage and Administration

The dosage of BCG depends on the clinical indication and the preparation used (e.g., TICE DRU Ita Co BCG). For tuberculosis prevention, BCG is administered as a single dose typically to infants. The dosage for bladder cancer treatment varies based on the protocol, with intravesical instillation being the method of administration.

1. Tuberculosis Prevention

  • Infants and Children: The standard dose of BCG for TB prevention is a single intradermal injection of approximately 0.1 mL of the vaccine.

  • Age and Health Status: In some countries, BCG may be given to newborns in areas with high rates of TB, but it is not recommended for people with compromised immune systems or those who have a history of TB exposure.

2. Bladder Cancer Treatment

  • Intravesical Administration: BCG for bladder cancer is administered via a catheter directly into the bladder. A typical treatment course involves weekly instillations for 6-12 weeks, followed by maintenance doses every 3-6 months for up to 3 years.

  • Preparation and Technique: The vaccine is diluted with sterile saline and instilled into the bladder. The patient must retain the solution for 2 hours to allow for maximal absorption by the bladder tissue.

Side Effects of BCG

Like all vaccines and treatments, BCG is not without potential side effects. While it is generally well tolerated, there are both mild and serious side effects that patients and healthcare providers should be aware of.

Common Side Effects

  • Local Reactions: After the BCG injection, patients may experience mild redness, swelling, or pain at the injection site. These reactions are generally temporary and resolve on their own.

  • Bladder Irritation: In bladder cancer treatment, patients may experience urgency, frequency, or painful urination as common side effects of intravesical BCG administration.

Serious Side Effects

  • Systemic Infection: In rare cases, BCG can cause disseminated BCG infection, especially in individuals with weakened immune systems. This can lead to severe complications like fever, malaise, and bacterial infections.

  • Tuberculosis: Although BCG is derived from a strain of M. bovis, there is a slight risk that the vaccine may cause BCG-induced TB in immunocompromised patients.

  • Bladder Cancer Complications: In patients undergoing BCG therapy for bladder cancer, there is a risk of hematuria (blood in the urine) and bladder spasms.

Contraindications and Safety Considerations

Contraindications

  • Immunocompromised Individuals: BCG should not be administered to individuals with HIV/AIDS, leukemia, lymphoma, or other immunodeficiencies, as they are at higher risk for developing severe side effects from the vaccine.

  • Pregnancy and Breastfeeding: BCG should generally be avoided during pregnancy and breastfeeding, unless the potential benefits outweigh the risks. It is considered Category C by the FDA.

Safety Considerations

  • Pre-treatment Screening: Patients receiving intravesical BCG therapy for bladder cancer should be carefully monitored for signs of urinary tract infections and systemic infections.

  • Follow-up: Patients who have received the BCG vaccine for bladder cancer treatment should undergo regular follow-up visits to monitor for recurrence and assess for potential side effects.

Conclusion

BCG is a critical tool in the fight against tuberculosis, with its use in preventing TB in children being well-established globally. Furthermore, its application in bladder cancer immunotherapy has significantly improved outcomes for patients with non-muscle-invasive disease. While generally safe, BCG therapy requires careful monitoring due to potential side effects and complications, particularly in immunocompromised patients. Ongoing research may expand its use in other cancers, further cementing BCG’s role in both infectious disease prevention and cancer treatment. As one of the oldest vaccines still in use today, Bacillus Calmette-Guérin remains a cornerstone of global health.